Table 3.
Prothrombin time (PT) and activated partial thromboplastin time (APTT) prolongation and plasma levels of rivaroxaban and melagatran 15 minutes after intravenous drug administration and 10 minutes after injection of tissue factor (TF)
| Drug dose (mg kg−1) | Rivaroxaban | Melagatran | ||
|---|---|---|---|---|
| Plasma concentration (μg L−1) | PT prolongation (x-fold over baseline) | Plasma concentration (μg L−1) | APTT prolongation (x-fold over baseline) | |
| Sham | – | 1.00 ± 0.03 | – | 1.00 ± 0.05 |
| TF control | – | 1.01 ± 0.03 | – | 1.23 ± 0.04 |
| 0.001 | 2.9 ± 0.4 | 1.00 ± 0.04 | <2.9† | 1.26 ± 0.05 |
| 0.003 | 4.8 ± 0.9 | 1.02 ± 0.02 | 6.3 ± 0.3 | 1.34 ± 0.05 |
| 0.01 | 15.4 ± 2.6 | 0.96 ± 0.02 | 19.2 ± 0.9 | 1.68 ± 0.03 |
| 0.03 | 60.7 ± 9.1 | 1.03 ± 0.02 | 45.9 ± 5.7 | 2.17 ± 0.23* |
| 0.1 | 276.8 ± 35.4 | 1.26 ± 0.06*** | 199.8 ± 25.8 | 2.08 ± 0.18** |
| 0.3 | 765.9 ± 68.0 | 1.92 ± 0.05*** | 524.7 ± 26.1 | 3.11 ± 0.27*** |
Results are shown as mean ± standard error of the mean.
*
P < 0.05
**
P < 0.01
***
P < 0.001 vs. sham control.
†Value below the detection limit of the assay.